ABOS
Price
$2.33
Change
+$0.21 (+9.91%)
Updated
Oct 14 closing price
Capitalization
140.83M
33 days until earnings call
Intraday Buy/Sell Signals
BEAM
Price
$25.42
Change
+$0.03 (+0.12%)
Updated
Oct 14 closing price
Capitalization
2.57B
26 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ABOS vs BEAM

Header iconABOS vs BEAM Comparison
Open Charts ABOS vs BEAMBanner chart's image
Acumen Pharmaceuticals
Price$2.33
Change+$0.21 (+9.91%)
Volume$401.93K
Capitalization140.83M
Beam Therapeutics
Price$25.42
Change+$0.03 (+0.12%)
Volume$2.03M
Capitalization2.57B
ABOS vs BEAM Comparison Chart in %
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABOS vs. BEAM commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a StrongBuy and BEAM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (ABOS: $2.12 vs. BEAM: $25.39)
Brand notoriety: ABOS and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 127% vs. BEAM: 104%
Market capitalization -- ABOS: $128.42M vs. BEAM: $2.57B
ABOS [@Biotechnology] is valued at $128.42M. BEAM’s [@Biotechnology] market capitalization is $2.57B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • BEAM’s FA Score: 1 green, 4 red.
According to our system of comparison, BEAM is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 6 TA indicator(s) are bullish while BEAM’s TA Score has 5 bullish TA indicator(s).

  • ABOS’s TA Score: 6 bullish, 5 bearish.
  • BEAM’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both ABOS and BEAM are a good buy in the short-term.

Price Growth

ABOS (@Biotechnology) experienced а +9.28% price change this week, while BEAM (@Biotechnology) price change was -1.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.86%. For the same industry, the average monthly price growth was +14.21%, and the average quarterly price growth was +268.76%.

Reported Earning Dates

ABOS is expected to report earnings on Nov 17, 2025.

BEAM is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+0.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.57B) has a higher market cap than ABOS($141M). ABOS YTD gains are higher at: 35.465 vs. BEAM (2.500). ABOS has higher annual earnings (EBITDA): -132.35M vs. BEAM (-414.33M). BEAM has more cash in the bank: 1.15B vs. ABOS (143M). ABOS has less debt than BEAM: ABOS (30.1M) vs BEAM (155M). BEAM has higher revenues than ABOS: BEAM (60.3M) vs ABOS (0).
ABOSBEAMABOS / BEAM
Capitalization141M2.57B5%
EBITDA-132.35M-414.33M32%
Gain YTD35.4652.5001,419%
P/E RatioN/AN/A-
Revenue060.3M-
Total Cash143M1.15B12%
Total Debt30.1M155M19%
TECHNICAL ANALYSIS
Technical Analysis
ABOSBEAM
RSI
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 7 days ago
89%
Momentum
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 12 days ago
77%
MACD
ODDS (%)
Bullish Trend 7 days ago
77%
N/A
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 7 days ago
78%
Advances
ODDS (%)
Bullish Trend 13 days ago
78%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 29 days ago
88%
Bearish Trend 19 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
90%
Aroon
ODDS (%)
Bearish Trend 7 days ago
88%
Bullish Trend 7 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MRPLY12.880.04
+0.33%
Mr. Price Group Ltd.
CYDX0.44N/A
N/A
CYduct Diagnostics Inc.
EVVTY75.75-0.54
-0.71%
Evolution AB
PAOTF10.91-0.09
-0.82%
Parrot Sa
USREF1.35-0.14
-9.40%
TACTICAL RES CORP.

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with KYTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then KYTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
+9.91%
KYTX - ABOS
43%
Loosely correlated
-2.45%
CELC - ABOS
43%
Loosely correlated
-2.55%
BEAM - ABOS
41%
Loosely correlated
+0.12%
CRBU - ABOS
40%
Loosely correlated
+2.52%
NMRA - ABOS
40%
Loosely correlated
-3.23%
More

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+0.12%
CRSP - BEAM
66%
Closely correlated
+1.60%
NTLA - BEAM
63%
Loosely correlated
+0.59%
RXRX - BEAM
61%
Loosely correlated
+6.51%
PRME - BEAM
55%
Loosely correlated
+6.02%
ABSI - BEAM
54%
Loosely correlated
+6.56%
More